natgillin/translations-raw huggingface dataset:
Symtuza 800 mg/150 mg/200 mg/10 mg filmovertrukne tabletter darunavir/cobicistat/emtricitabin/tenofoviralafenamid 
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets darunavir/cobicistat/emtricitabine/tenofovir alafenamide
Naturlægemidler Perikon (Hypericum perforatum) 
Herbal products St. John's wort (Hypericum Perforatum)
4.5) - dabigatran, ticagrelor 
simvastatin, lovastatin and lomitapide (see section 4.5) - dabigatran, ticagrelor
Hvis der opstår tegn og symptomer på alvorlige hudreaktioner, skal Symtuza straks seponeres. 
Symtuza should be discontinued immediately if signs or symptoms of severe skin reactions develop.
Hvis indiceret, kan det være nødvendigt at indlede behandling af hepatitis B. Hos patienter med fremskreden leversygdom eller cirrose frarådes seponering, da forværring af hepatitis efter behandlingen kan føre til nedsat leverfunktion. 
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
Navn og adresse på den fremstiller (de fremstillere), der er ansvarlig(e) for batchfrigivelse 
Name and address of the manufacturer(s) responsible for batch release Janssen-Cilag SpA
6 celler/mm 
6 cells/mm 3 (range
Symtuza er ikke blevet undersøgt hos patienter med nedsat leverfunktion. 
Symtuza has not been investigated in patients with hepatic impairment.
Genotypebestemmelse bør være vejledende for brugen af Symtuza (se pkt. 
Genotypic testing should guide the use of Symtuza (see sections 4.2, 4.4, and 5.1).
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse sedativa/hypnotika. 
Based on theoretical considerations DRV/COBI is expected to increase these sedative/hypnotic plasma concentrations.
Baseret på teoretiske overvejelser forventes rifampicin at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat og/eller tenofoviralafenamid. 
Based on theoretical considerations rifampicin is expected to decrease darunavir and/or cobicistat and/or tenofovir alafenamide plasma concentrations.
var 23 % (interval: 7-45 %). 
95-1,110), and median CD4+ % was 23% (range: 7-45%).
Tenofoviralafenamid hæmmer ikke CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 eller CYP2D6 in vitro. 
Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 in vitro.
5.1) eller med hiv-1 RNA ≥ 100.000 kopier/ml eller CD4+-celletal < 100 celler x 10 
Symtuza should not be used in treatment-experienced patients with one or more DRV-RAMs (see section 5.1) or with HIV-1 RNA ≥ 100,000 copies/mL or CD4+ cell count < 100 cells x 10
Det skal du vide, før du begynder at tage Symtuza Sådan skal du tage Symtuza Bivirkninger 
What Symtuza is and what it is used for What you need to know before you take Symtuza How to take Symtuza
Blødninger hos patienter med hæmofili 
Bleeding in haemophiliac patients
Baseret på teoretiske overvejelser kan DRV/COBI øge plasmakoncentrationen af methadon. 
Based on theoretical considerations DRV/COBI may increase methadone plasma concentrations.
Forsøgsdeltagere, 
Subjects,
Baseret på teoretiske overvejelser forventes bosentan at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat. 
Based on theoretical considerations bosentan is expected to decrease darunavir and/or cobicistat plasma concentrations.
Amiodaron, dronedaron, ivabradin, kinidin, eller ranolazin til behandling af visse hjertelidelser (f.eks. unormal hjerterytme) Carbamazepin, phenobarbital og phenytoin til forebyggelse af krampeanfald Colchicin (hvis du har nyre-/leverproblemer) 
Carbamazepine, phenobarbital and phenytoin to prevent seizures Colchicine (if you have kidney/liver problems) to treat gout The combination product lopinavir/ritonavir anti-HIV medicine
4.5) - rifampicin - sekalealkaloider (f.eks. dihydroergotamin, ergometrin, ergotamin, methylergometrin) - dapoxetin - domperidon - naloxegol - pimozid, quetiapin, sertindol, lurasidon (se pkt. 
Co-administration with the following medicinal products due to the potential for serious and/or life-threatening adverse reactions (see section 4.5): - alfuzosin - amiodarone, dronedarone, ivabradine, quinidine, ranolazine - colchicine when used in patients with renal and/or hepatic impairment (see section 4.5) - rifampicin - ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine) - dapoxetine - domperidone - naloxegol - pimozide, quetiapine, sertindole, lurasidone (see section 4.5) - triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse neuroleptika. 
Based on theoretical considerations DRV/COBI is expected to increase these neuroleptic plasma concentrations.
Baseret på teoretiske overvejelser kan DRV/COBI muligvis ændre plasmakoncentrationen af warfarin. 
Based on theoretical considerations DRV/COBI may alter warfarin plasma concentrations.
(Induktion af CYP3A og/eller P-gp). 
(CYP3A and/or P-gp induction).
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af digoxin. 
Based on theoretical considerations DRV/COBI is expected to increase digoxin plasma concentrations.
(Hæmning af CYP3A og/eller P-glykoprotein). 
(CYP3A and/or P-glycoprotein inhibition).
Baseret på teoretiske overvejelser forventes disse antimykobakterielle midler at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat og/eller tenofoviralafenamid. 
Based on theoretical considerations these antimycobacterials are expected to decrease darunavir and/or cobicistat and/or tenofovir alafenamide plasma concentrations.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse kortikosteroider. 
Based on theoretical considerations DRV/COBI is expected to increase these corticosteroid plasma concentrations.
Det frarådes at co-administrere Symtuza med bosentan. 
Co-administration of Symtuza and bosentan is not recommended.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af salmeterol. 
Based on theoretical considerations DRV/COBI is expected to increase salmeterol plasma concentrations.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af alfentanil. 
Based on theoretical considerations DRV/COBI is expected to increase alfentanil plasma concentrations.
Tidligere ARV-svigt 
It may harm them,
(Hæmning af CYP3A og/eller P-glykoprotein) 
(CYP3A and/or P-glycoprotein inhibition)
(Induktion af CYP3A og/eller P-gp) 
(CYP3A and/or P-gp induction)
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse immunsuppresiva. 
Based on theoretical considerations DRV/COBI is expected to increase these immunosuppressant plasma concentrations.
4.5) - sildenafil til behandling af pulmonal arteriel hypertension, avanafil, simvastatin, lovastatin og lomitapid (se pkt. 
see section 4.5) - sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil,
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af simeprevir. 
Based on theoretical considerations DRV/COBI is expected to increase simeprevir plasma concentrations.
Baseret på teoretiske overvejelser kan DRV/COBI ændre plasmakoncentrationen af norethisteron. 
Based on theoretical considerations DRV/COBI may alter norethindrone plasma concentrations.
Tabletkerne 
30 tablets
Baseret på teoretiske overvejelser kan DRV/COBI øge eksponeringen for sekalealkaloider. 
Based on theoretical considerations DRV/COBI may increase ergot derivative exposure.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af colchicin. 
Based on theoretical considerations DRV/COBI is expected to increase colchicine plasma concentrations.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af metformin. 
Based on theoretical considerations DRV/COBI is expected to increase metformin plasma concentrations.
- Fentanyl, oxycodon, tramadol (til smertebehandling) - Fesoterodin, solifenacin (til behandling af sygdomme i urinvejene). 
- Fesoterodine, solifenacin (to treat urologic disorders).
- Rifabutin (mod bakterieinfektioner). 
- Clonazepam (to prevent seizures).
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse antidepressiva. 
Based on theoretical considerations DRV/COBI is expected to increase these anti-depressant plasma concentrations.
Baseret på teoretiske overvejelser forventes disse antiepileptika at nedsætte plasmakoncentrationen af darunavir og/eller cobicistat og/eller tenofoviralafenamid. 
Based on theoretical considerations these anticonvulsants are expected to decrease darunavir and/or cobicistat and/or tenofovir alafenamide plasma concentrations.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse PDE-5-hæmmere. 
Based on theoretical considerations DRV/COBI is expected to increase these PDE-5 inhibitor plasma concentrations.
Dog skal Symtuza anvendes med forsigtighed hos sådanne patienter, eftersom indholdsstofferne darunavir og cobicistat i Symtuza metaboliseres i leveren. 
No dose adjustment of Symtuza is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, Symtuza should be used with caution in these patients, as the darunavir and cobicistat components of Symtuza are metabolised by the hepatic system.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse antiarytmika. 
Based on theoretical considerations DRV/COBI is expected to increase these antiarrhythmic plasma concentrations.
Co-administration af perikon og Symtuza er kontraindiceret (se pkt. 
Co-administration of Symtuza and ergot derivatives is contraindicated (see section 4.3).
4.5): - carbamazepin, phenobarbital, phenytoin - rifampicin - lopinavir/ritonavir - perikon (Hypericum perforatum) 
- lopinavir/ritonavir - St. John's wort (Hypericum perforatum)
- Amitriptylin, desipramin, imipramin, nortriptylin, paroxetin, sertralin, trazodon (til behandling af depression og angst). 
- Rifabutin (against bacterial infections) - Tadalafil, sildenafil, vardenafil (for erectile dysfunction or high blood pressure in the pulmonary circulation) - Amitriptyline, desipramine, imipramine, nortriptyline, paroxetine, sertraline, trazodone (to treat depression and anxiety) - Perphenazine, risperidone, thioridazine (psychiatric medicines) - Ciclosporin, everolimus, tacrolimus, sirolimus (for dampening down your immune system) as the therapeutic effect or side effects of these medicines might be increased.
Du skal fortælle det til din læge, hvis du tager: - Alfentanil (stærkt smertestillende middel til injektion med kort virkningstid, der anvendes ved operationer). 
Tell your doctor if you take: - Alfentanil (injectable, strong and short-acting, painkiller that is used for surgical procedures) - Carvedilol, metoprolol, timolol (for heart disease) - Warfarin (to reduce clotting of the blood) as its therapeutic effect or side effects may be altered;
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af lumefantrin. 
Based on theoretical considerations DRV/COBI is expected to increase lumefantrine plasma concentrations.
4.5): - alfuzosin - amiodaron, dronedaron, ivabradin, kinidin, ranolazin - colchicin ved anvendelse hos patienter med nedsat nyre- eller leverfunktion (se pkt. 
Amiodarone, dronedarone, ivabradine, quinidine, or ranolazine to treat certain heart disorders (e.g. abnormal heart rhythm)
Ved co-administration med Symtuza er terapeutisk lægemiddelovervågniong af det immunsupprimerende middel nødvendig. 
Therapeutic drug monitoring of the immunosuppressive agent must be done when co-administration with Symtuza occurs.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse betablokkere. 
Based on theoretical considerations DRV/COBI is expected to increase these beta-blocker plasma concentrations.
Baseret på teoretiske overvejelser forventes DRV/COBI at øge plasmakoncentrationen af disse calciumantagonister. 
Based on theoretical considerations DRV/COBI is expected to increase these calcium channel blocker plasma concentrations.
Effekten af svært nedsat leverfunktion på darunavirs farmakokinetik er ikke blevet undersøgt (se pkt. 
The effect of severe hepatic impairment on the pharmacokinetics of darunavir has not been studied (see sections 4.2, 4.3 and 4.4).
En enkelt dosis på 
A single dose of
NovoSeven fik en markedsføringstilladelse med gyldighed i hele EU den 23. februar 1996. 
NovoSeven received a marketing authorisation valid throughout the EU on 23 February 1996.
Børn kan have behov for en højere dosis. 
A higher dose may be needed in children.
Det anvendes til patienter med følgende lidelser: 
It is used in patients with the following conditions:
Andre oplysninger om NovoSeven 
Other information about NovoSeven
Yderligere information om NovoSeven findes på agenturets websted under: ema.europa.eu/medicines/human/EPAR/novoseven. 
Further information on NovoSeven can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/novoseven.
Som for alle lægemidler bliver data vedrørende brug af NovoSeven løbende overvåget. 
As for all medicines, data on the use of NovoSeven are continuously monitored.
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af NovoSeven? 
What measures are being taken to ensure the safe and effective use of NovoSeven?
Det aktiverer en anden faktor kaldet faktor X, som iværksætter størkningsprocessen. 
It activates another factor called factor X, which starts the clotting process.
En oversigt over NovoSeven, og hvorfor det er godkendt i EU 
An overview of NovoSeven and why it is authorised in the EU
Patienterne eller deres plejere kan selv indgive NovoSeven, når de er blevet behørigt instrueret heri. 
Patients or carers may be able to give NovoSeven themselves after suitable training.
Hvorfor blev NovoSeven godkendt i EU? 
Why is NovoSeven authorised in the EU?
For mere information om brug af NovoSeven, se indlægssedlen eller kontakt lægen eller apotekspersonalet. 
For more information about using NovoSeven, see the package leaflet or contact your doctor or pharmacist.
Det Europæiske Lægemiddelagentur konkluderede, at fordelene ved NovoSeven opvejer risiciene, og at det kan godkendes til anvendelse i EU. 
The European Medicines Agency decided that NovoSeven's benefits are greater than its risks and it can be authorised in the EU..
Bivirkninger rapporteret for NovoSeven vurderes omhyggeligt, og der tages de nødvendige forholdsregler for at beskytte patienterne. 
Side effects reported with NovoSeven are carefully evaluated and any necessary action taken to protect patients.
Virkningen blev hovedsagelig bedømt på antallet af blødningsepisoder, som effektivt blev kontrolleret. 
The main measure of effectiveness was the number of bleeding episodes that were controlled effectively.
270 mikrogram/kg kan anvendes til voksne med en mild til moderat blødningsepisode. 
270 micrograms/kg may be used in adults with a mild or moderate bleeding episode.
Hvad er NovoSeven, og hvad anvendes det til? 
What is NovoSeven and what is it used for?
• Glanzmanns trombasteni (en sjælden blødningsforstyrrelse), som ikke kan behandles med transfusion af blodplader (komponenter, der hjælper blodet til at størkne). 
• Glanzmann's thrombasthenia (a rare bleeding disorder) who cannot be treated with a transfusion of platelets (components that help the blood to clot).
Dog kan følgende bivirkninger optræde hos mellem 1 og 10 ud af 1.000 patienter: venøse tromboemboliske komplikationer (problemer forårsaget af blodpropper i venerne), udslæt, kløe, urticaria (nældefeber), feber og nedsat virkning af behandling. 
However the following side effects may affect between 1 and 10 patients in 1,000: venous thromboembolic events (problems caused by blood clots in the veins), rash, pruritus (itching), urticaria (hives), fever and reduced effectiveness of treatment.
NovoSeven kan også anvendes til at erstatte den manglende faktor VII hos patienter med faktor VII-mangel. 
NovoSeven can also be used to replace the missing factor VII in patients with factor VII deficiency.
Eptacog alfa virker på samme måde som faktor VII. 
Eptacog alfa works in the same way as factor VII.
Ved at aktivere faktor X giver NovoSeven en midlertidig kontrol over blødningsforstyrrelsen. 
By activating factor X, NovoSeven is able to give temporary control of the bleeding disorder.
Hvilke risici er der forbundet med NovoSeven? 
What are the risks associated with NovoSeven?
NovoSeven er et lægemiddel, der anvendes til behandling og forebyggelse af blødning efter kirurgiske indgreb. 
NovoSeven is a medicine used to treat and to prevent bleeding after surgical procedures.
Der blev indsamlet data vedrørende brugen af NovoSeven hos patienter med Glanzmanns trombasteni fra et register over patienter behandlet med lægemidlet, som viste, at behandlingen med NovoSeven var vellykket ved 79 % af blødningsepisoderne (262 ud af 333) og 88 % af de kirurgiske indgreb (140 ud af 159). 
Data on the use of NovoSeven in patients with Glanzmann's thrombasthenia were obtained from a registry of patients treated with the medicine, which showed that treatment with NovoSeven was successful in 79% of the bleeding episodes (262 out of 333) and 88% of the surgeries (140 out of
NovoSeven må ikke anvendes til personer, som er overfølsomme (allergiske) over for eptacog alfa, muse-, hamster- eller okseproteiner eller andre af indholdsstofferne. 
NovoSeven must not be used in people who are hypersensitive (allergic) to eptacog alfa, to mouse, hamster or cow proteins, or to any of the other ingredients.
Det aktive stof i NovoSeven, eptacog alfa, er næsten identisk med et humant protein kaldet faktor VII. 
The active substance in NovoSeven, eptacog alfa, is almost identical to a human protein called factor VII.
I et studie, som omfattede 61 hæmofilipatienter med inhibitorer, blev 84 % af de 57 svære blødninger og 59 % af de 38 kirurgiske blødninger effektivt kontrolleret med NovoSeven. 
In a study involving 61 haemophilia patients with inhibitors, 84% of the 57 serious bleeds and 59% of the 38 surgical bleeds were controlled effectively with NovoSeven.
I et andet studie, som omfattede 60 patienter med milde til moderate blødningsepisoder, hvor det blev undersøgt, om NovoSeven kunne anvendes i hjemmet, blev 90 % af blødningsepisoderne effektivt kontrolleret. 
In another study in 60 patients with mild to moderate bleeding episodes, which investigated whether NovoSeven could be used in the home setting, 90% of the bleeding episodes were controlled effectively.
Det leveres som pulver og solvens, der blandes til en opløsning til indsprøjtning i en vene. 
It is available as a powder and solvent that are made up into a solution to be injected into a vein.
Faktor VII er i kroppen medvirkende til, at blodet størkner. 
In the body, factor VII is involved in blood clotting.
• medfødt faktor VII-mangel 
• congenital factor VII deficiency;
• Ved faktor VII-mangel gives der en dosis på 15-30 mikrogram/kg hver fjerde til sjette time, indtil blødningen er under kontrol. 
• In factor VII deficiency, the dose is 15 to 30 micrograms/kg every 4 to 6 hours until the bleeding is controlled.
NovoSeven indeholder det aktive stof eptacog alfa. 
NovoSeven contains the active substance eptacog alfa.
• Ved Glanzmanns trombasteni gives der en dosis på 90 mikrogram/kg hver anden time, og der gives mindst tre doser. 
• In Glanzmann's thrombasthenia, the dose is 90 micrograms/kg every 2 hours, for at least three doses.
NovoSeven udleveres kun efter recept, og behandlingen bør iværksættes under opsyn af en læge med erfaring i behandling af hæmofili eller blødningsforstyrrelser. 
NovoSeven can only be obtained with a prescription and treatment and should be started under the supervision of a doctor who has experience in the treatment of haemophilia or bleeding disorders.
NovoSeven er blevet undersøgt hos patienter med hæmofili og patienter med faktor VII-mangel. 
NovoSeven has been studied in patients with haemophilia and in patients with factor VII deficiency.
• medfødt hæmofili (en blødningsforstyrrelse, som er til stede allerede fra fødslen), hvor patienten har udviklet eller forventes at udvikle "inhibitorer" (antistoffer) mod faktor VIII eller IX 
• congenital haemophilia (a bleeding disorder present from birth) who have developed or are expected to develop ‘inhibitors' (antibodies) against factor VIII or IX;
• erhvervet hæmofili (en blødningssygdom, der skyldes udvikling af inhibitorer mod faktor VIII) 
• acquired haemophilia (a bleeding disease caused by the development of inhibitors to factor VIII);
Almindeligvis forekommer der ikke bivirkninger ved NovoSeven. 
Side effects with NovoSeven are not common.
Hvilke fordele viser studierne, at der er ved NovoSeven? 
What benefits of NovoSeven have been shown in studies?
Den fuldstændige liste over bivirkninger ved NovoSeven fremgår af indlægssedlen. 
For the full list of side effects of NovoSeven, see the package leaflet.
• Ved hæmofili er dosis 90 mikrogram pr. kilo kropsvægt gentaget hver anden til tredje time, indtil blødningen er under kontrol. 
• In haemophilia, the dose is 90 micrograms per kilogram body weight, repeated every 2 to 3 hours until the bleeding is controlled.
Hvordan anvendes NovoSeven? 
How is NovoSeven used?
Der er anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af NovoSeven. 
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of NovoSeven have been included in the summary of product characteristics and the package leaflet.
NovoSeven kan anvendes til hæmofilipatienter, som har udviklet inhibitorer mod faktor VIII og IX, fordi faktor VII indvirker direkte på faktor X, uafhængigt af faktor VIII og IX. 
Because factor VII acts directly on factor X, independently from factors VIII and IX, NovoSeven can be used in haemophilia patients who have developed inhibitors to factor VIII or IX.
Hvordan virker NovoSeven? 
How does NovoSeven work?
Udløbsdatoen henviser til den sidste dag i den måned. 
The expiry date refers to the last day of that month.
De ajourførte retningslinjer blev fastlagt på konsensusmødet Maastricht 22000. 
The updated guidelines were established during the Maastricht 22000 Consensus meeting.
Den sædvanlige dosis er 
The usual dose is
Følg din læges anbefalinger. 
Please follow your doctor's recommendations
Det kan skade dem, selvom de fremviser symptomer, der ligner dine. 
It may harm them, even if their symptoms are the same as yours.
Indflydelsen fra denne kombinerede administration er endnu ikke systematisk undersøgt. 
The influence of this combined administration has not yet been investigated systemically.
Virkning* 
Effect*
Dosering og varighed af kombineret administration 
Dosage and duration of combined administration
Dette blev ikke set hos aber, hunde eller mus. 
This was not seen in monkeys, dogs or mice.
Dette lægemiddel virker bedst, når det tages på tom mave. 
This medicine has the best effect when taken into empty stomach.
- De andre indholdsstoffer er: 
- The other ingredients are:
Absorption og fordeling: 
Absorption and distribution:
Der er ingen ændring i halveringstiden under behandling. 
There is no change in half-life during treatment.
“Mulige bivirkninger”). 
“Possible side effects”).
Benefit/risk-forholdet 
Benefit/Risk considerations
SÆRLIGE FORHOLDSREGLER FOR BORTSKAFFELSE AF UBRUGTE LÆGEMIDLER ELLER AFFALDSMATERIALER AFLEDT FRA SÅDANNE LÆGEMIDLER, HVIS PASSENDE 
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
7, 10, 10x1, 14, 14x1, 20, 28, 28x1, 30, 30x1, 56, 56x1, 60, 98, 98x1, 100 og 100x1 kapsler Ikke alle pakningsstørrelser bliver muligvis markedsført. 
7, 10, 10x1, 14, 14x1, 20, 28, 28x1, 30, 30x1, 56, 56x1, 60, 98, 98x1, 100 and 100x1 capsules Not all pack sizes may be marketed.